Funding Reductions Could Reverse Progress in HIV Response
By Elana Gotkine HealthDay Reporter
THURSDAY, March 27, 2025 -- Funding reductions could reverse progress in the HIV response by 2030, with the greatest effects anticipated in countries with a higher percentage of international funding and with increasing incidence of HIV, according to a study published online March 26 in The Lancet HIV.
Debra ten Brink, M.D., from the Burnet Institute in Australia, and colleagues used 26 country-validated Optima HIV models to examine the potential impact of funding reductions on HIV incidence and mortality through mathematical modeling. HIV incidence and mortality were projected across 2025 to 2030 for a status quo scenario (continuation of most recent HIV spending) and four additional scenarios reflecting anticipated international aid reductions for HIV prevention and testing plus additional effects from immediate discontinuation of the President's Emergency Fund for AIDS Relief (PEPFAR) support.
The researchers found that an anticipated 24 percent weighted average of international aid reductions plus discontinued PEPFAR support could result in an additional 4.43 to 10.75 million new HIV infections and 0.77 to 2.93 million HIV-related deaths from 2025 to 2030 (compared with the status quo) across all low-income and middle-income countries. These numbers reduced to 0.07 to 1.73 million additional new HIV infections and 0.005 to 0.061 million HIV-related deaths if PEPFAR support could be reinstated or recovered. Countries with a higher percentage of international funding had the greatest effects, as did those with an increasing incidence of HIV among key populations.
"The temporary suspension of U.S. Government support combined with other anticipated reductions in international aid for HIV presents an inflection point, compelling the global health community to reassess sustainable financing strategies of the HIV response," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.